185 related articles for article (PubMed ID: 2987424)
1. Phase II study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation. Preliminary report.
Decker DA; Al Sarraf M; Kresge C; Austin D; Wilner HI
J Neurooncol; 1985; 3(1):19-21. PubMed ID: 2987424
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.
Feun LG; Yung WK; Leavens ME; Burgess MA; Obbens EA; Bedikian AY; Savaraj N; Stewart DJ; Benjamin RS; Fields WS
J Neurooncol; 1984; 2(1):13-7. PubMed ID: 6088722
[TBL] [Abstract][Full Text] [Related]
3. Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
Greenberg HS; Ensminger WD; Layton PB; Gebarski S; Meyer M; Chaffee B; Bender JF; Grillo-Lopez AJ
Cancer Treat Rep; 1986 Mar; 70(3):353-7. PubMed ID: 3006913
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors.
Chamberlain MC; Prados MD; Silver P; Levin VA
J Neurooncol; 1988 Dec; 6(4):319-23. PubMed ID: 3221259
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive phase II evaluation of aziridinylbenzoquinone (AZQ, diaziquone) in recurrent human primary brain tumors.
Eagan RT; Dinapoli RP; Cascino TL; Scheithauer B; O'Neill BP; O'Fallon JR
J Neurooncol; 1987; 5(4):309-14. PubMed ID: 3440875
[TBL] [Abstract][Full Text] [Related]
6. Preliminary communication--treatment of primary brain tumors recurrent after irradiation with aziridinylbenzoquinone (AZQ;NSC-182986).
Eagan RT; Dinapoli RP; Hermann RC; Groover RV; Layton DD
Am J Clin Oncol; 1983 Oct; 6(5):577-8. PubMed ID: 6613923
[TBL] [Abstract][Full Text] [Related]
7. Response rate and toxicity with aziridinylbenzoquinone in patients with recurrent gliomas. A progress report.
Tapazoglou E; Kish J; Ensley J; Al-Sarraf M
Am J Clin Oncol; 1988 Aug; 11(4):474-8. PubMed ID: 3407628
[TBL] [Abstract][Full Text] [Related]
8. Effect of AZQ (1,4-cyclohexadiene-1,4-diacarbamic acid-2,5-bis(1-aziridinyl)-3,6 -dioxodiethylester) in recurring supratentorial malignant brain gliomas--a Phase II study. EORTC Brain Tumour Cooperative Group.
Eur J Cancer Clin Oncol; 1985 Jan; 21(1):143-6. PubMed ID: 4038653
[No Abstract] [Full Text] [Related]
9. Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors. A Pediatric Oncology Group phase II study.
Castleberry RP; Ragab AH; Steuber CP; Kamen B; Toledano S; Starling K; Norris D; Burger P; Krischer JP
Invest New Drugs; 1990 Nov; 8(4):401-6. PubMed ID: 2084075
[TBL] [Abstract][Full Text] [Related]
10. Treatment of metastatic breast cancer with AZQ: a phase II trial.
Martino S; Ratanatharathorn V; Samal BA; Singhakowinta A; Haas C
Cancer Invest; 1988; 6(3):289-91. PubMed ID: 3167612
[TBL] [Abstract][Full Text] [Related]
11. An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
Halperin EC; Gaspar L; Imperato J; Salter M; Herndon J; Dowling S
Am J Clin Oncol; 1993 Aug; 16(4):277-83. PubMed ID: 8392285
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical evaluation of AZQ in adenocarcinoma of the lung.
Decker DA; Samson MK; Haas CD; Baker LH
Am J Clin Oncol; 1984 Aug; 7(4):353-5. PubMed ID: 6741865
[TBL] [Abstract][Full Text] [Related]
13. Aziridinylbenzoquinone in recurrent, progressive glioma of the central nervous system. A Phase II study by the Illinois Cancer Council.
Haid M; Khandekar JD; Christ M; Johnson CM; Miller SJ; Locker GY; Merrill JM; Reisel H; Hatfield A; Lanzotti V
Cancer; 1985 Sep; 56(6):1311-5. PubMed ID: 4027870
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory lymphoma.
McLaughlin P; Cabanillas F; Bedikian AY; Bodey GP
Cancer Treat Rep; 1983 May; 67(5):507-8. PubMed ID: 6850666
[No Abstract] [Full Text] [Related]
15. Phase II clinical evaluation of AZQ in renal cell carcinoma.
Decker DA; Kish J; Al-Sarraf M; Goldfarb S
Am J Clin Oncol; 1986 Apr; 9(2):126-8. PubMed ID: 3717078
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of aziridinylbenzoquinone (AZQ) in patients with central nervous system malignancies: a Southwest Oncology Group Study.
Taylor SA; McCracken JD; Eyre HJ; O'Bryan RM; Neilan BA
J Neurooncol; 1985; 3(2):131-5. PubMed ID: 2993536
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of an aziridinylbenzoquinone (AZQ) in disseminated malignant melanoma.
Creagan ET; Schutt AJ; Ahmann DL; Green SJ
Cancer Treat Rep; 1982 Dec; 66(12):2089-90. PubMed ID: 7139650
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory small cell carcinoma of the lung.
Fuks JZ; Aisner J; Van Echo DA; Levitt M; Ihde DC; Carney D; Wiernik PH
Am J Clin Oncol; 1983 Apr; 6(2):171-3. PubMed ID: 6299094
[TBL] [Abstract][Full Text] [Related]
19. Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas.
Curt GA; Kelley JA; Kufta CV; Smith BH; Kornblith PL; Young RC; Collins JM
Cancer Res; 1983 Dec; 43(12 Pt 1):6102-5. PubMed ID: 6640549
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with recurrent primary brain tumors with AZQ.
Schold SC; Friedman HS; Bjornsson TD; Falletta JM
Neurology; 1984 May; 34(5):615-9. PubMed ID: 6538653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
